The Institute for Clinical and Economic Review will use Aetion observational real-world evidence to evaluate potential drugs from Takeda and CSL Behring.
The two companies have partnered to develop a systemic erythematosus assessment review to streamline clinical trials centered on the autoimmune disease.
The collaboration centers on development of precision cancer treatments, through discovery and validation of next-generation DNA damage response targets.
Leaders from the supply chain solutions company share their thoughts on challenges associated with virtual and hybrid trials, and the COVID-19 pandemic.
New research findings suggest that an immunotherapy assay enables determination of PD-L1 status in a high percentage of cancer patients and could guide personalized treatment selection.
The AWARE for All virtual event series aims to educate and engage the public as important partners in clinical trials and development of new treatments.
An expert from FourKites shares impacts of the February storm that hit Texas and other parts of North America, and lessons can be learned from the event.
A leader from the global CRO discusses how putting the patient first in clinical research is essential to discovering new therapies for orphan diseases.
Especially with the COVID-19 pandemic impacting studies, the company says, putting patients at the center of studies and trial tech must be top priority.
A father of two boys with Duchenne muscular dystrophy is running the Austin Marathon to raise funds toward pursuit of a cure for the rare, fatal disease.
The free Patient-Centric Trial Development Toolkit is aimed toward helping sites and sponsors identify and minimize risks in rare-disease clinical studies.
